Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium picosulfate + magnesium salts (often formulated as sodium picosulfate, magnesium oxide, and anhydrous citric acid) is a low-volume, dual-mechanism bowel cleansing preparation. It is widely used to clear the colon in preparation for colonoscopy, endoscopy, or bowel surgery. The combination functions through two distinct mechanisms: sodium picosulfate is a prodrug that is metabolized by colonic bacteria into the active stimulant laxative 4,4'-dihydroxy-diphenyl-[2-pyridyl]methane (BHPM), which promotes colonic peristalsis; meanwhile, magnesium oxide and citric acid react in water to form magnesium citrate, an osmotic laxative that retains water in the gastrointestinal tract. Together, these components produce a powerful purgative effect with high patient compliance due to the low volume required. It is marketed under various brand names, including PICOLAX, PICOPREP, PREPOPIK, and CLENPIQ, and was developed by companies such as Norgine and Ferring Pharmaceuticals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium picosulfate + magnesium salts.